Success Metrics

Clinical Success Rate
91.0%

Based on 332 completed trials

Completion Rate
91%(332/365)
Active Trials
157(23%)
Results Posted
3%(10 trials)
Terminated
33(5%)

Phase Distribution

Ph phase_2
13
2%
Ph phase_4
14
2%
Ph not_applicable
329
48%
Ph phase_3
9
1%
Ph early_phase_1
3
0%
Ph phase_1
8
1%

Phase Distribution

11

Early Stage

13

Mid Stage

23

Late Stage

Phase Distribution376 total trials
Early Phase 1First-in-human
3(0.8%)
Phase 1Safety & dosage
8(2.1%)
Phase 2Efficacy & side effects
13(3.5%)
Phase 3Large-scale testing
9(2.4%)
Phase 4Post-market surveillance
14(3.7%)
N/ANon-phased studies
329(87.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.3%

332 of 376 finished

Non-Completion Rate

11.7%

44 ended early

Currently Active

157

trials recruiting

Total Trials

684

all time

Status Distribution
Active(186)
Completed(332)
Terminated(44)
Other(122)

Detailed Status

Completed332
Recruiting133
unknown121
Terminated33
Not yet recruiting26
Active, not recruiting24

Development Timeline

Analytics

Development Status

Total Trials
684
Active
157
Success Rate
91.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (0.8%)
Phase 18 (2.1%)
Phase 213 (3.5%)
Phase 39 (2.4%)
Phase 414 (3.7%)
N/A329 (87.5%)

Trials by Status

not_yet_recruiting264%
active_not_recruiting244%
completed33249%
recruiting13319%
terminated335%
unknown12118%
suspended10%
withdrawn112%
enrolling_by_invitation30%

Recent Activity

Clinical Trials (684)

Showing 20 of 684 trialsScroll for more
NCT05616338Not Applicable

Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)

Completed
NCT07557628

Study of the Hypothalamic Microglial Response as a Function of a Meal's Lipid Content in Humans. A Single-center Prospective Cohort Study in Healthy Male Subjects

Recruiting
NCT07686653

A Study of the Value of Trio Genome Sequencing in the Etiological Evaluation of Early-Onset and/or Atypical Psychiatric Disorders Without Intellectual Disability or Congenital Anomalies

Recruiting
NCT07827989Not Applicable

Study of the Impact of Phosphate Supplementation on FGF23 Concentrations in Patients With Hypophosphatemia

Recruiting
NCT06762002

Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort

Recruiting
NCT02453620Phase 1

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Active Not Recruiting
NCT07820566

Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)

Recruiting
NCT03190577Not Applicable

Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology

Completed
NCT05710679Not Applicable

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Recruiting
NCT07812012

The Potential of Mesenchymal Stromal Stem Cells to Correct Immune and Metabolic Dysfunctions in Circulating Immune Cells During Sepsis: An Ex Vivo Pilot Study.

Not Yet Recruiting
NCT06594315

Assessing Brain Metabolism Using MRS With Deuterated Glucose

Recruiting
NCT06895681

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

Withdrawn
NCT05388838Not Applicable

Screening for Oculocerebral Lymphoma With the Phenotype of NK Cells in Patients With Uveitis

Completed
NCT05798338

Characterization of Extracellular Vesicles in Breast Cancer Patients

Recruiting
NCT06021548

Biopsychosocial Markers of Addiction in Opioid Users: an Integrated Approach

Recruiting
NCT03890601

New Biological Tests in Patients With Antiphospholipid Antibodies

Completed
NCT07226466

Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

Not Yet Recruiting
NCT02902874Not Applicable

Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

Completed
NCT03698071Not Applicable

Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

Completed
NCT01823263Not Applicable

Metabolic and Cognitive Parameters Following Partial Sleep Deprivation

Completed

Drug Details

Intervention Type
OTHER
Total Trials
684